Human Pre-Cancer Models

人类癌症前期模型

基本信息

  • 批准号:
    10518851
  • 负责人:
  • 金额:
    $ 17.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-15 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Core 2: Human Pre-Cancer Models (HPM) Core The Human Pre-Cancer Models (HPM) Core will serve as a central repository for generation, propagation, and characterization of pre-cancer colonic organoids and isolation of neutrophils and patient-matched cytotoxic/CD8+ T cells as well as providing technical expertise to conduct key experiments. The HPM Core will provide support to all three projects and interact closely with the Quantitative Biosciences (QB) Core. The HPM Core’s resource building will facilitate proposed projects and hypothesis generation for future pilot and feasibility studies. During subsequent years of the grant, larger collaborative efforts (within TBEL and elsewhere) will be supported by the HPM Core as capability and expertise expand. The HPM Core will leverage existing, institutionally- supported infrastructure and equipment to provide a full range of fully-annotated human colonic organoids (normal, SSL, and adenoma). All the organoids in these studies will have an extensive record of participant information and whole-exome sequencing (WES) along with matched germline DNA. The HPM Core will leverage resources from COLON MAP for acquisition of pre-cancer specimens and experience from the GI SPORE projects where we have established preclinical models of colorectal cancer (CRC) including patient- derived CRC xenografts (PDXs) and organoids (PDOs). The HPM Core is established to support the overall goal of the TBEL application in determining how the microenvironment of colonic pre-cancer lesions is shaped by its individual components (epithelial, microbial, stroma, and immune cells). The HPM Core will coordinate efforts, consolidate resources, and share experimental expertise by pursuing three Specific Aims: 1) generate and characterize epithelial, stromal, and microbial components of pre-cancer lesions; 2) establish culture and co-culture conditions of epithelial cells with colibactin- producing E. coli and immune and/or stromal components; and 3) manipulate colonic organoids via genetic and pharmacologic perturbations. The immediate goal of the HPM Core is to provide support to all three of our projects and QB core. Core personnel will work closely with project and core leaders to ensure effective support and two-way communication. The longer-term goal of the HPM Core is the wider dissemination of these resources and expertise as we welcome the opportunity to provide support to other TBEL recipients.
项目摘要/摘要 核心2:人类癌前模型(HPM)核心 人类癌前模型(HPM)核心将作为生成、传播和 癌前结肠类器官的表征和中性粒细胞和患者匹配的细胞毒性/CD 8+的分离 T细胞以及提供技术专长进行关键实验。HPM核心将提供支持 所有三个项目,并与定量生物科学(QB)的核心密切互动。HPM核心 资源建设将促进拟议项目和为今后的试点和可行性研究提出假设。 在接下来的几年里,更大的合作努力(在TBEL和其他地方)将得到支持 随着能力和专业知识的扩展,HPM核心将利用现有的,制度上的- 支持的基础设施和设备,以提供全方位的完整注释的人类结肠类器官 (正常、SSL和腺瘤)。这些研究中的所有类器官都将有大量的参与者记录, 沿着匹配的种系DNA的全外显子组测序(WES)。HPM核心将 利用COLON MAP的资源获取癌前标本和GI经验 SPORE项目,我们已经建立了结直肠癌(CRC)的临床前模型,包括患者- 衍生的CRC异种移植物(PDX)和类器官(PDO)。 建立HPM核心是为了支持TBEL应用程序的总体目标,以确定 结肠癌前病变的微环境由其单个组分(上皮,微生物, 基质和免疫细胞)。HPM核心将协调工作,整合资源,并共享实验 通过追求三个特定目标的专业知识:1)产生和表征上皮,基质和微生物 癌前病变的成分; 2)建立上皮细胞与大肠杆菌素的培养和共培养条件, 产生E.大肠杆菌和免疫和/或基质组分;和3)通过遗传和免疫调控来操纵结肠类器官。 药理学干扰。 HPM核心的近期目标是为我们的所有三个项目和QB核心提供支持。核心 工作人员将与项目和核心领导人密切合作,以确保有效的支持和双向沟通。 HPM核心的长期目标是更广泛地传播这些资源和专业知识, 欢迎有机会为其他TBL接受者提供支持。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bhuminder Singh其他文献

Bhuminder Singh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bhuminder Singh', 18)}}的其他基金

Human Pre-Cancer Models
人类癌症前期模型
  • 批准号:
    10697378
  • 财政年份:
    2022
  • 资助金额:
    $ 17.56万
  • 项目类别:
Role of Receptor Tyrosine Kinase cross-talk in colorectal cancer
受体酪氨酸激酶串扰在结直肠癌中的作用
  • 批准号:
    10404504
  • 财政年份:
    2021
  • 资助金额:
    $ 17.56万
  • 项目类别:
Role of Receptor Tyrosine Kinase cross-talk in colorectal cancer
受体酪氨酸激酶串扰在结直肠癌中的作用
  • 批准号:
    10616532
  • 财政年份:
    2021
  • 资助金额:
    $ 17.56万
  • 项目类别:

相似海外基金

Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.56万
  • 项目类别:
    Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
  • 批准号:
    2897580
  • 财政年份:
    2023
  • 资助金额:
    $ 17.56万
  • 项目类别:
    Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
  • 批准号:
    10658324
  • 财政年份:
    2023
  • 资助金额:
    $ 17.56万
  • 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
  • 批准号:
    10794761
  • 财政年份:
    2023
  • 资助金额:
    $ 17.56万
  • 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
  • 批准号:
    2304430
  • 财政年份:
    2023
  • 资助金额:
    $ 17.56万
  • 项目类别:
    Cooperative Agreement
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 17.56万
  • 项目类别:
    Fellowship
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
  • 批准号:
    23K15543
  • 财政年份:
    2023
  • 资助金额:
    $ 17.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
  • 批准号:
    10976161
  • 财政年份:
    2023
  • 资助金额:
    $ 17.56万
  • 项目类别:
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
  • 批准号:
    10720234
  • 财政年份:
    2023
  • 资助金额:
    $ 17.56万
  • 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
  • 批准号:
    10721983
  • 财政年份:
    2023
  • 资助金额:
    $ 17.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了